58791-87-0 Usage
Explanation
The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 10 carbon (C) atoms, 8 hydrogen (H) atoms, 1 chlorine (Cl) atom, and 5 nitrogen (N) atoms.
Explanation
The compound is derived from the pyrazolopyrimidine ring system, which is a fused ring structure consisting of a pyrazole and a pyrimidine.
Explanation
The compound contains two specific functional groups a 3-chlorophenyl group (a phenyl ring with a chlorine atom at the 3rd position) and an aminopyrimidine group (a pyrimidine ring with an amino group attached).
Explanation
Due to its unique structure and functional groups, the compound may have biological activity and could be used in the development of new drugs.
Explanation
The compound's structure suggests that it may have interesting interactions with enzymes or receptors in the body, which could be exploited for therapeutic purposes.
Explanation
Given its potential applications and biological activity, 1-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine is considered a valuable compound for further investigation in the field of pharmaceutical research.
Chemical structure
Pyrazolopyrimidine derivative
Substituents
3-chlorophenyl and aminopyrimidine groups
Potential applications
Pharmaceutical research
Biological activity
Interactions with enzymes or receptors
Further investigation
Valuable compound for research
Check Digit Verification of cas no
The CAS Registry Mumber 58791-87-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,7,9 and 1 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 58791-87:
(7*5)+(6*8)+(5*7)+(4*9)+(3*1)+(2*8)+(1*7)=180
180 % 10 = 0
So 58791-87-0 is a valid CAS Registry Number.
58791-87-0Relevant articles and documents
Mnk1 or Mnk2 inhibitors
-
Page/Page column 14, (2008/06/13)
The present invention relates to novel pharmaceutical compositions comprising pyrazolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrazolopyrimidine compounds of the invention for the production of pharmaceutical compos